Area of research
Oncology · Immunology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Immunotherapy and Immune Responses.
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity
High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
Diagnostic and Prognostic Biomarkers of Chronic Pancreatitis: A Conceptual Framework Based on the PRoBE Design
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Lymph Node Subcapsular Sinus Microenvironment-On-A-Chip Modeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing
Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer
IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs
Clinical and molecular markers of immune checkpoint inhibitor (ICI) response in dMMR colorectal cancer (CRC) patients (pts).
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation
Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function